Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1%

Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1% Ahmedabad, India, 26 April, 2024 Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Tretinoin Cream USP, 0.1%, (USRLD: Retin-A Cream, 0.1%). Tretinoin cream is used to treat acne. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India). Tretinoin Cream USP, 0.1% had annual sales of USD 54.8 mn in the United States (IQVIA MAT Feb-24). The group now has 39 4 approvals and has so far filed over 4 60* ANDAs since the commencement of the filing process in FY 2003-04. (*as of 31st December 2023) ****

The release as fetched from its publisher. zyduslife.com ↗